JP2023551122A - 化合物およびタキキニン受容体介在性障害の治療におけるその使用 - Google Patents

化合物およびタキキニン受容体介在性障害の治療におけるその使用 Download PDF

Info

Publication number
JP2023551122A
JP2023551122A JP2023528102A JP2023528102A JP2023551122A JP 2023551122 A JP2023551122 A JP 2023551122A JP 2023528102 A JP2023528102 A JP 2023528102A JP 2023528102 A JP2023528102 A JP 2023528102A JP 2023551122 A JP2023551122 A JP 2023551122A
Authority
JP
Japan
Prior art keywords
nk2r
group
amino acids
agonist
agonist according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2023528102A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023551122A5 (enExample
Inventor
バーント フレデリク グスタフソン，マグナス
マッドセン，ジョニー
ムルバッド，オリビア
フレデリク ジョアン ホーゲンドーフ，ウォウター
ボンド ハンセン，ジェイコブ
Original Assignee
エンバーク バイオテック エーピーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エンバーク バイオテック エーピーエス filed Critical エンバーク バイオテック エーピーエス
Publication of JP2023551122A publication Critical patent/JP2023551122A/ja
Publication of JP2023551122A5 publication Critical patent/JP2023551122A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023528102A 2020-11-09 2021-11-09 化合物およびタキキニン受容体介在性障害の治療におけるその使用 Ceased JP2023551122A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20206509.0 2020-11-09
EP20206509 2020-11-09
PCT/EP2021/081057 WO2022096736A1 (en) 2020-11-09 2021-11-09 Compounds and their use in treatment of tachykinin receptor mediated disorders

Publications (2)

Publication Number Publication Date
JP2023551122A true JP2023551122A (ja) 2023-12-07
JP2023551122A5 JP2023551122A5 (enExample) 2024-10-30

Family

ID=73198203

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528102A Ceased JP2023551122A (ja) 2020-11-09 2021-11-09 化合物およびタキキニン受容体介在性障害の治療におけるその使用

Country Status (13)

Country Link
US (1) US20230406883A1 (enExample)
EP (1) EP4240749A1 (enExample)
JP (1) JP2023551122A (enExample)
KR (1) KR20230106616A (enExample)
CN (1) CN116745310A (enExample)
AU (1) AU2021374843A1 (enExample)
CA (1) CA3197916A1 (enExample)
CL (1) CL2023001325A1 (enExample)
CO (1) CO2023007404A2 (enExample)
IL (1) IL302745A (enExample)
MX (1) MX2023005408A (enExample)
PE (1) PE20231952A1 (enExample)
WO (1) WO2022096736A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
WO2023118263A1 (en) * 2021-12-21 2023-06-29 Embark Biotech Aps Agonists for treatment of eating disorder
CN117384258B (zh) * 2023-10-12 2024-07-26 湖南中晟全肽生物科技股份有限公司 一种神经激肽受体2（nk2r）激动剂及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017505284A (ja) * 2013-11-15 2017-02-16 ノヴォ ノルディスク アー／エス 選択的なｐｙｙ化合物及びその使用
JP2018522843A (ja) * 2015-06-12 2018-08-16 ノヴォ ノルディスク アー／エス 選択的ｐｙｙ化合物及びその使用
WO2019059963A1 (en) * 2017-09-21 2019-03-28 Dignify Therapeutics, Llc COMPOSITIONS FOR INDUCING MICTION AND DEFECATION

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2660247A3 (en) * 2009-05-08 2014-09-03 Chongxi Yu High penetration prodrug compositions of peptides and peptide-related compounds
CA2918245C (en) * 2013-08-01 2022-08-30 Dignify Therapeutics, Inc. Compositions and methods for inducing urinary voiding and defecation
PE20210473A1 (es) * 2018-05-04 2021-03-08 Novo Nordisk As Derivados de gip y usos de estos
KR20220084035A (ko) * 2019-10-17 2022-06-21 유니버시티 오브 코펜하겐 Tacr2의 효능제

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017505284A (ja) * 2013-11-15 2017-02-16 ノヴォ ノルディスク アー／エス 選択的なｐｙｙ化合物及びその使用
JP2018522843A (ja) * 2015-06-12 2018-08-16 ノヴォ ノルディスク アー／エス 選択的ｐｙｙ化合物及びその使用
WO2019059963A1 (en) * 2017-09-21 2019-03-28 Dignify Therapeutics, Llc COMPOSITIONS FOR INDUCING MICTION AND DEFECATION

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAU J. ET AL.: "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analpgues Semaglutide", J MED CHEM, vol. 58, JPN6025044138, 2015, pages 7370 - 7380, ISSN: 0005723006 *

Also Published As

Publication number Publication date
PE20231952A1 (es) 2023-12-06
WO2022096736A1 (en) 2022-05-12
US20230406883A1 (en) 2023-12-21
CA3197916A1 (en) 2022-05-12
CL2023001325A1 (es) 2023-12-15
MX2023005408A (es) 2023-07-25
AU2021374843A1 (en) 2023-06-08
KR20230106616A (ko) 2023-07-13
AU2021374843A9 (en) 2024-08-08
CO2023007404A2 (es) 2023-07-10
EP4240749A1 (en) 2023-09-13
IL302745A (en) 2023-07-01
CN116745310A (zh) 2023-09-12

Similar Documents

Publication Publication Date Title
KR102440323B1 (ko) 인크레틴 유사체 및 그의 용도
KR102444783B1 (ko) 인크레틴 유사체 및 그의 용도
US12410227B2 (en) Incretin analogs and uses thereof
US7186694B2 (en) Leptin-related peptides
JP3765831B2 (ja) 改善された環状ｃｒｆ作用薬
US20230406883A1 (en) Compounds and their use in treatment of tachykinin receptor mediated disorders
JP2022509568A (ja) 修飾されたｇｉｐペプチド類似体
KR102476550B1 (ko) 선택적인 pyy 화합물 및 그것의 사용
CN1976948A (zh) 修饰的Exendins及其应用
KR20110043686A (ko) 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드의 유사체
JPH11505521A (ja) グルカゴン様ペプチド−２、ならびにその治療への使用
US7208572B2 (en) Leptin-related peptides
US11572399B2 (en) Long-acting GIP peptide analogues
WO2023207107A1 (zh) Glp-1/gcg受体共激动剂、包含其的药物组合物及其用途
CN100425282C (zh) 用于治疗性干预的y2/y4选择性受体激动剂
KR20250140094A (ko) Gip/glp1/gcg 삼중-수용체 효능제 및 그의 용도
KR20190017017A (ko) 프로테아제-내성 모노-지질화된 펩타이드
AU2005224027A1 (en) Y2/Y4 selective receptor agonists for therapeutic interventions
US20070161545A1 (en) Triple polypeptide complexes
WO2023207106A1 (zh) Glp-1/gip受体共激动剂、包含其的药物组合物及其用途
EA049082B1 (ru) Соединения и их применение для лечения нарушений, опосредованных тахикининовым рецептором
EA043728B1 (ru) Аналоги инкретина и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230921

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20231129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231129

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231130

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260203

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260210

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20260630